Price movement over the last 24 hours
Abeona Therapeutics Inc vs Advanced Drainage Systems Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Advanced Drainage Systems Inc trades at $145.16 (market cap $11.42B). The key difference: Advanced Drainage Systems Inc is far larger — about 30.6× Abeona Therapeutics Inc's market cap, and Advanced Drainage Systems Inc pays a 0.54% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | WMS | |
|---|---|---|
Market Cap | $373.32M | $11.42B |
Sector | Health | Industrials |
52-Week High | $7.23 | $175.38 |
52-Week Low | $4.17 | $110.89 |
Enterprise Value | $228.22M | $12.99B |
Dividend Yield | — | 0.54% |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Advanced Drainage Systems (WMS) trades at $149.07, down 2.04% over 24 hours. The stock shows strong profitability with a 13.98% net income margin and consistent earnings beats in recent quarters. Technical indicators are bullish overall, with moving averages supporting an uptrend. Recent news includes a dividend increase and mixed analyst sentiment, with a consensus price target of $183.00. Cash flow trends indicate robust operational performance despite a recent dip in net cash flow.
Outlook remains positive due to solid fundamentals and growth in stormwater management demand. Risks include competitive pressures and potential margin compression. The stock presents a moderate buy opportunity with upside to analyst targets, balanced by near-term volatility and sector-specific headwinds.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →